A review of patent literature on the regulation of glucose metabolism by six phytocompounds in the management of diabetes mellitus and its complications

Cole, 2020, Genetics of diabetes mellitus and diabetes complications, Nat Rev Nephrol, 16, 377, 10.1038/s41581-020-0278-5 Altaf, 2015, Novel therapeutics for type 2 diabetes: insulin resistance, Diabetes Obes Metab, 17, 319, 10.1111/dom.12400 Davoudi, 2015, Novel genetic actors of diabetes-associated microvascular complications: retinopathy, kidney disease, and neuropathy, Rev Diabet Stud, 12, 243, 10.1900/RDS.2015.12.243 Golden, 2019, Racial/ethnic differences in the burden of type 2 diabetes over the life course: a focus on the USA and India, Diabetologia, 62, 1751, 10.1007/s00125-019-4968-0 Pradeepa, 2017, Prevalence of type 2 diabetes and its complications in India and economic costs to the nation, Eur J Clin Nutr, 71, 816, 10.1038/ejcn.2017.40 Vaughan, 2020, Reducing the burden of diabetes treatment: a review of low-cost oral hypoglycemic medications, Curr Diabetes Rev, 16, 851, 10.2174/1573399816666200206112318 Wu, 2020, An overview of prospective drugs for type 1 and type 2 diabetes, Curr Drug Targets, 21, 445, 10.2174/1389450120666191031104653 Wang, 2013, Treating type 2 diabetes mellitus with traditional Chinese and Indian medicinal herbs, Evid Based Complement Alternat Med, 2013 Jugran, 2021, Diabetes and plant-derived natural products: from ethnopharmacological approaches to their potential for modern drug discovery and development, Phytother Res, 35, 223, 10.1002/ptr.6821 Tran, 2020, Bioactive compounds in anti-diabetic plants: from herbal medicine to modern drug discovery, Biology, 9, 252, 10.3390/biology9090252 Nabavi, 2015, Curcumin: a natural product for diabetes and its complications, Curr Top Med Chem, 15, 2445, 10.2174/1568026615666150619142519 Imran, 2017, Mangiferin: a natural miracle bioactive compound against lifestyle related disorders, Lipids Health Dis, 16, 1, 10.1186/s12944-017-0449-y Pang, 2015, Application of berberine on treating type 2 diabetes mellitus, Int J Endocrinol, 2015, 10.1155/2015/905749 Semwal, 2015, Gingerols and shogaols: important nutraceutical principles from ginger, Phytochemistry, 117, 554, 10.1016/j.phytochem.2015.07.012 Tiwari, 2014, Phytochemical and pharmacological properties of Gymnema sylvestre: an important medicinal plant, Biomed Res Int, 2014, 10.1155/2014/830285 Choudhury, 2018, An update on natural compounds in the remedy of diabetes mellitus: a systematic review, J Tradit Complement Med, 8, 361, 10.1016/j.jtcme.2017.08.012 Carpino, 2010, Diabetes area participation analysis: a review of companies and targets described in the 2008–2010 patent literature, Expert Opin Ther Patents, 20, 1627, 10.1517/13543776.2010.533171 Heng MCY. WO2000070949—Method for using soluble curcumin to inhibit phosphorylase kinase in inflammatory diseases. (2000-11-30) [2022-01-01]. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2000070949. Mae T, Misuzu T, Hideyuki K, Mitsuaki K, Mikio K, Kaku N, et al. US20030147979A1 Ligand for peroxisome proliferator-activated receptor. (2002-10-23) [2022-01-01]. https://worldwide.espacenet.com/patent/search/family/019141144/publication/US2003147979A1?q=US20030147979. Allan G, Kelley G. CA2510295—Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents. (2003-12-18) [2022-01-01]. https://patentscope.wipo.int/search/en/detail.jsf?docId=CA94148266&_cid=P21-KXEK1R-13261-1. Wellen CW. WO2005113069—Use of curcumin and analogues as inhibitors of ACC2. (2005-05-13) [2022-01-01]. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2005113069&_cid=P21-KXEK2U-13637-1. Tortoriello D, Weisberg SP. US20100240581—Selective proteasome inhibitors for treating diabetes. (2010-09-23) [2022-01-01]. https://patentscope.wipo.int/search/en/detail.jsf?docId=US43365498&_cid=P11-L96QLI-02216-1. Chen W, Lou Z, Yin X. CN1434053—Rhizoma anemarrhenae extract and preparation process and use thereof. (2003-08-06) [2022-01-01]. https://patentscope.wipo.int/search/en/detail.jsf?docId=CN82627484&_cid=P11-L96QJ8-00980-1. Xu C, Sun L, Jiang X, Zhang Y, Zhu L, Xiang Y, et al. CN100998601—Medicine for treating type 2 diabetes and its estimation model. (2007-07-18) [2022-01-01]. https://patentscope.wipo.int/search/en/detail.jsf?docId=CN83193727&_cid=P11-L96QO6-03663-1. Wu QY, Chen WS, Hu HG, Zhao QJ, Liao HL, Xu JM, et al. CN101003558—Glycoside class compound of mango, preparation method, and application in area of medicine. (2007-07-25) [2022-01-01]. https://patentscope.wipo.int/search/en/detail.jsf?docId=CN83197151&_cid=P21-KXEK3Z-13998-1. Zhang Y, Wang T, Han LF, Liu EW, Ge DD, Gao XM, et al. CN101693034—Diffractive-ring mangiferin A in mango leaves and new application of mango leaf extractives containing diffractive-ring mangiferin A. (2011-08-17) [2022-01-01]. https://patentscope.wipo.int/search/en/detail.jsf?docId=CN83886331&_cid=P21-KXEK6J-14995-1. Song YY, Gao H, Tang K. CN111317830—Research method for pharmacologic action of mangiferin on mouse diabetes. (2020-06-23) [2022-01-01]. https://patentscope.wipo.int/search/en/detail.jsf?docId=CN298613390&_cid=P21-KXEKC8-17411-1. Ning G, Zhang ZG, Jin LN, Han LY, Yuan YN, Wang H. CN110179793—Application of berberine in preparation of medicines for metabolic diseases. (2019-08-30) [2022-01-01]. https://patentscope.wipo.int/search/en/detail.jsf?docId=CN251464759&_cid=P21-KXEN1A-47952-1. Ning G, Li X, Zhang Y, Hong J, Gu W, Zhang Z, et al. CN101219141—Use of berberine in treating metabolism complex. (2008-07-16) [2022-01-01]. https://patentscope.wipo.int/search/en/detail.jsf?docId=CN83416193&_cid=P11-L96RA5-13845-1. Ning G, Tang HJ, Zhou LB, Wang X, Li FY, Liu Y, et al. CN104055772A Application of berberine in inhibition of expression of gene PPP1R3C. (2014-09-24) [2022-01-01]. https://worldwide.espacenet.com/patent/search/family/051543892/publication/CN104055772A?q=CN%20104055772A. Luan DG, Qin LY, Luan SP, Sun KZ. CN106749228 A—Berberine drug as well as preparation method and application thereof. (2017-05-31). [2022-01-01]. https://patentscope.wipo.int/search/en/detail.jsf?docId=CN198447475&_cid=P11-L96RRN-22156-1. Ning G, Wang N, Zhou LB, Wang X. CN103040821A—Application of berberine in pharmacy. (2013-04-17) [2022-01-01]. https://patentscope.wipo.int/search/en/detail.jsf?docId=CN85993211&_cid=P11-L96RUT-23414-1. Wei J, Jiang J, Wang Z. CN1393264—Application of berberine as sensibilizer of insulin. (2003-01-29) [2022-01-01]. https://patentscope.wipo.int/search/en/detail.jsf?docId=CN82586151&_cid=P11-L96RXS-25093-1. Yamazaki Y, Kono Y, Kamibayashi M. JP2011001386—Adiponectin production enhancer. (2011-01-06) [2022-01-01]. https://patentscope.wipo.int/search/en/detail.jsf?docId=JP272709592&_cid=P22-L981DO-10423-1. Ueno A, Tsuda T, Yoshikawa T. JP2006249064A—Therapeutic/preventive agent for diabetes and/or obesity, method and kit for evaluating antidiabetic and/or antiobesity action, and method and kit for screening antidiabetics and/or antiobesity material. (2006-09-21) [2022-01-01]. https://patentscope.wipo.int/search/en/detail.jsf?docId=JP270848321&_cid=P22-L981HG-11671-1. Kamble B, Gupta A, Patil D, Pathak D, Basavan D. IN4130/CHE/2012—Pure gymnemagenin, or its salts, ethers or esters or its polymeric nanoparticles with potent antidiabetic and anti-hyper-lipidaemic activity. (2012-11-02) [2022-01-01]. https://patentscope.wipo.int/search/en/detail.jsf?docId=IN211567854&_cid=P22-L981L5-12990-1. Panda BP, Sheoran S. IN2198/DEL/2015—Gymnema sylvestre extract with enriched gymnemagenin shows superior antidiabetic effect under in vitro and in vivo conditions. (2017-01-27) [2022-01-01]. https://patentscope.wipo.int/search/en/detail.jsf?docId=IN211791599&_cid=P22-L981NZ-13920-1. Mukherjee, 2018, Exploring synergy in ayurveda and traditional Indian systems of medicine, Synergy, 7, 30, 10.1016/j.synres.2018.10.003 Yin J. CN105055413A Medicine composition of berberine and repaglinide. (2015-07-23) [2022-01-01]. https://worldwide.espacenet.com/patent/search/family/054485098/publication/CN105055413A?q=CN105055413. Ji Y, Zhou K, Su XY, Zhou LB, Guo L, Wang YQ, et al. CN103271907A Oral medicine composition consisting of berberine and melbine, and preparation method thereof. (2013-05-30) [2022-01-01]. https://worldwide.espacenet.com/patent/search/family/049054132/publication/CN103271907A?q=CN103271907A. Ji, 2018, Effect of combination of Bifidobacterium and berberine on pre-diabetes and type 2 diabetes, Trials, 19, 72 Prasad, 2014, Curcumin, a component of golden spice: from bedside to bench and back, Biotechnol Adv, 32, 1053, 10.1016/j.biotechadv.2014.04.004 Donath, 2010, Cytokine production by islets in health and diabetes: cellular origin, regulation and function, Trends Endocrinol Metab, 21, 261, 10.1016/j.tem.2009.12.010 Scheen, 2018, Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors, Circ Res, 122, 1439, 10.1161/CIRCRESAHA.117.311588 Hung, 2012, Comparative effectiveness of incident oral antidiabetic drugs on kidney function, Kidney Int, 81, 698, 10.1038/ki.2011.444 Lee, 2021, Plant extracts for type 2 diabetes: from traditional medicine to modern drug discovery, Antioxidants (Basel), 10, 81, 10.3390/antiox10010081 Feher, 2017, Chapter 2.9 ATP production I: glycolysis, 218 Wakil, 2009, Fatty acid metabolism: target for metabolic syndrome, J Lipid Res, 50, S138, 10.1194/jlr.R800079-JLR200